
    
      The vaccination will be given in three injections, at Day 0, Day 7, and Day 28, respectively,
      based on the Advisory Committee on Immunization Practice (ACIP) and the World Health
      Organization (WHO) recommendations for pre-exposure regimen. A booster dose will be
      administered 1 year after the first vaccine injection in a randomized subset of participants.

      Safety will be assessed in all participants up to 28 days after vaccination, as applicable,
      in terms of occurrence of adverse events (AEs), and serious adverse events (SAEs) and adverse
      events of special interest (AESIs) up to Month 12.
    
  